Last reviewed · How we verify
DRV/r
DRV/r is a Protease inhibitor (boosted) Small molecule drug developed by Community Research Initiative of New England. It is currently FDA-approved for HIV-1 infection in treatment-experienced patients, HIV-1 infection in treatment-naive patients.
DRV/r is a combination of darunavir (a protease inhibitor) boosted with ritonavir (a pharmacokinetic enhancer) that blocks HIV protease to prevent viral replication.
DRV/r is a combination of darunavir (a protease inhibitor) boosted with ritonavir (a pharmacokinetic enhancer) that blocks HIV protease to prevent viral replication. Used for HIV-1 infection in treatment-experienced patients, HIV-1 infection in treatment-naive patients.
At a glance
| Generic name | DRV/r |
|---|---|
| Sponsor | Community Research Initiative of New England |
| Drug class | Protease inhibitor (boosted) |
| Target | HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Darunavir inhibits the HIV protease enzyme, preventing the cleavage of viral polyproteins necessary for the production of mature, infectious viral particles. Ritonavir is a potent cytochrome P450 inhibitor that boosts darunavir plasma concentrations by inhibiting its metabolism, allowing lower doses of darunavir to achieve therapeutic levels. Together, DRV/r suppresses HIV viral load in treatment-experienced and treatment-naive patients.
Approved indications
- HIV-1 infection in treatment-experienced patients
- HIV-1 infection in treatment-naive patients
Common side effects
- Diarrhea
- Nausea
- Headache
- Rash
- Abdominal pain
- Elevated liver enzymes
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV (PHASE1, PHASE2)
- Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
- Ndovu RCT: Investing the Optimal Management of Dolutegravir Resistance (PHASE3)
- Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine (PHASE3)
- Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen (PHASE2)
- Patients' Experiences and Perceptions of 3TC/DTG Dual Therapy (the PEDAL Study)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DRV/r CI brief — competitive landscape report
- DRV/r updates RSS · CI watch RSS
- Community Research Initiative of New England portfolio CI
Frequently asked questions about DRV/r
What is DRV/r?
How does DRV/r work?
What is DRV/r used for?
Who makes DRV/r?
What drug class is DRV/r in?
What development phase is DRV/r in?
What are the side effects of DRV/r?
What does DRV/r target?
Related
- Drug class: All Protease inhibitor (boosted) drugs
- Target: All drugs targeting HIV protease
- Manufacturer: Community Research Initiative of New England — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for HIV-1 infection in treatment-experienced patients
- Indication: Drugs for HIV-1 infection in treatment-naive patients
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing